🔴 AIM ImmunoTech is trading 5% down today with no clear company-specific catalyst identified

AIM ImmunoTech is trading 5.06% down now at $0.21 after no clear company-specific catalyst was identified for September 18, 2026.

• CEO Thomas Equels purchased 24,000 shares for $4,992 on September 17, a supportive disclosure rather than an obvious explanation for the decline.
• The broader biotechnology sector is rising, while major U.S. indexes are mixed; neither clearly explains the drop.
• The move currently appears driven by trading activity or sentiment rather than confirmed news.